CHMP recommends EU conditional approval of Roche’s potential first-in-class bispecific antibody mosunetuzumab for people with relapsed or refractory follicular lymphoma April 22, 2022April 22, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: European Commission approves Roche’s first-in-class…FDA approves Roche’s Lunsumio, a first-in-class…FDA grants priority review to Roche’s bispecific…FDA grants Priority Review to Roche’s Lunsumio for…New pivotal data demonstrate clinical benefit of…New pivotal data demonstrate clinical benefit of…
